Alexander Sherry

1/ Tremendous thanks to the patients, coauthors and all who made the EXTEND trial possible. The primary aggregated analysis is now available online @JCO_ASCO with ctDNA correlatives presented synchronously at @ESTRO_RT #ESTRO26

Does the addition of MDT to standard of care continuous ADT improve outcomes for oligomet prostate ca?

Happy to share the results of EXTEND evaluating this question alongside PI @ChadTangMD & many others

Curious to know the probability of treatment effects from your favorite RCT, but don't have the underlying data? Check out our recent work in @JCOPO_ASCO developing a prior, customized for phase III oncology, requiring only summary stats (HR + 95% CI).
doi.org/10.1200/PO.24.…

RNCTs promise group-specific inference, which they are unable to deliver, and undermine the primary advantage of randomization, which is comparative inference. We urge reconsideration of the ongoing use of this paradoxical design @PavlosMsaouel @ebludmir pubmed.ncbi.nlm.nih.gov/39313076/

Multivariable analyses for strong prognostic factors, even in randomized trials, can boost statistical power. Here, we find that favorable power gains from MVA meaningfully translate to improved odds of meeting the primary endpoints of oncology phase III randomized trials.